Publication:
Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization

dc.contributor.coauthorEsai Selvan, Myvizhi
dc.contributor.coauthorBhere, Deepak
dc.contributor.coauthorShah, Khalid
dc.contributor.departmentSchool of Medicine
dc.contributor.departmentKUTTAM (Koç University Research Center for Translational Medicine)
dc.contributor.facultymemberYes
dc.contributor.kuauthorCingöz, Ahmet
dc.contributor.kuauthorGümüş, Zeynep Hülya
dc.contributor.kuauthorMorova, Tunç
dc.contributor.kuauthorÖnder, Tuğba Bağcı
dc.contributor.kuauthorÖzyerli, Ezgi
dc.contributor.kuauthorŞeker-Polat, Fidan
dc.contributor.kuauthorSolaroğlu, İhsan
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.contributor.schoolcollegeinstituteResearch Center
dc.date.accessioned2024-11-09T22:49:39Z
dc.date.issued2021
dc.description.abstractTumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces tumor cell-specific apoptosis, making it a prime therapeutic candidate. However, many tumor cells are either innately TRAIL-resistant, or they acquire resistance with adaptive mechanisms that remain poorly understood. In this study, we generated acquired TRAIL resistance models using multiple glioblastoma (GBM) cell lines to assess the molecular alterations in the TRAIL-resistant state. We selected TRAIL-resistant cells through chronic and long-term TRAIL exposure and noted that they showed persistent resistance both in vitro and in vivo. Among known TRAIL-sensitizers, proteosome inhibitor Bortezomib, but not HDAC inhibitor MS-275, was effective in overcoming resistance in all cell models. This was partly achieved through upregulating death receptors and pro-apoptotic proteins, and downregulating major anti-apoptotic members, Bcl-2 and Bcl-xL. We showed that CRISPR/Cas9 mediated silencing of DR5 could block Bortezomib-mediated re-sensitization, demonstrating its critical role. While overexpression of Bcl-2 or Bcl-xL was sufficient to confer resistance to TRAIL-sensitive cells, it failed to override Bortezomib-mediated re-sensitization. With RNA sequencing in multiple paired TRAIL-sensitive and TRAIL-resistant cells, we identified major alterations in inflammatory signaling, particularly in the NF-kappa B pathway. Inhibiting NF-kappa B substantially sensitized the most resistant cells to TRAIL, however, the sensitization effect was not as great as what was observed with Bortezomib. Together, our findings provide new models of acquired TRAIL resistance, which will provide essential tools to gain further insight into the heterogeneous therapy responses within GBM tumors. Additionally, these findings emphasize the critical importance of combining proteasome inhibitors and pro-apoptotic ligands to overcome acquired resistance.
dc.description.fulltextNo
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessNO
dc.description.peerreviewstatusN/A
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuTÜBİTAK
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TUBITAK) [3501]
dc.description.sponsorshipMarie Curie FP7 Career Reintegration Grant (EC) [618673]
dc.description.sponsorshipBAGEP
dc.description.sponsorshipNIH/NCI [U24 CA210993]
dc.description.sponsorshipIcahn Institute
dc.description.sponsorshipNIH [R01CA201148]
dc.description.sponsorshipPresidency of Turkey, Presidency of Strategy and Budget Financial support was obtained from The Scientific and Technological Research Council of Turkey (TUBITAK) (3501), Marie Curie FP7 Career Reintegration Grant (EC Grant # 618673), and BAGEP. ZHG and ME acknowledge NIH/NCI U24 CA210993 and start-up funds from the Icahn Institute. KS acknowledges the NIH R01CA201148. The authors gratefully acknowledge the use of services and facilities of the Koc University Research Center for Translational Medicine (KUTTAM), funded by the Presidency of Turkey, Presidency of Strategy and Budget.
dc.description.studentonlypublicationNo
dc.description.studentpublicationYes
dc.description.versionN/A
dc.identifier.WoSQuartileQ1
dc.identifier.doi10.1038/s41388-021-01697-6
dc.identifier.eissn1476-5594
dc.identifier.embargoN/A
dc.identifier.endpage3216
dc.identifier.grantno3501
dc.identifier.issn0950-9232
dc.identifier.issue18
dc.identifier.pubmed33767436
dc.identifier.scopus2-s2.0-85103166221
dc.identifier.startpage3201
dc.identifier.urihttps://doi.org/10.1038/s41388-021-01697-6
dc.identifier.urihttps://hdl.handle.net/20.500.14288/6543
dc.identifier.volume40
dc.identifier.wos000632820300004
dc.keywordsApoptosis
dc.keywordsApoptosis regulatory proteins
dc.keywordsTNF-related apoptosis-inducing ligand
dc.keywordsProto-oncogene proteins c-bcl-2
dc.language.isoeng
dc.publisherSpringer Nature
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofOncogene
dc.relation.openaccessN/A
dc.relation.projectIdentification of TRAIL sensivity/resistance mechanisms and searching for novel TRAIL-sensitizing agents in Glioblastoma Multiforme
dc.relation.projectGlioblastoma Multiform (Gbm) Tümörlerini Trial (TumorNecrosis Factor Related Apoptosis Inducing Ligand)`E Duyarlılığını Etkileyen Faktörlerin Belirlenmesi ve Trail`E Duyarlılığı Arttırıcı Yeni Kimyasalların Bulunması
dc.rightsN/A
dc.subjectBiochemistry
dc.subjectMolecular biology
dc.subjectOncology
dc.subjectCell biology
dc.subjectGenetics
dc.subjectHeredity
dc.titleGeneration of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorCingöz, Ahmet
local.contributor.kuauthorÖzyerli, Ezgi
local.contributor.kuauthorMorova, Tunç
local.contributor.kuauthorŞeker-Polat, Fidan
local.contributor.kuauthorGümüş, Zeynep Hülya
local.contributor.kuauthorSolaroğlu, İhsan
local.contributor.kuauthorÖnder, Tuğba Bağcı
relation.isGoalOfPublicationa9786601-9431-4553-9a46-013bb366fb87
relation.isGoalOfPublication.latestForDiscoverya9786601-9431-4553-9a46-013bb366fb87
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication91bbe15d-017f-446b-b102-ce755523d939
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublicationd437580f-9309-4ecb-864a-4af58309d287
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isProjectOfPublication4cdaf710-171b-449f-abbe-94c85e6073e9
relation.isProjectOfPublicationa8e106d9-8c19-4c9e-bd91-7cc98e9a4125
relation.isProjectOfPublication.latestForDiscovery4cdaf710-171b-449f-abbe-94c85e6073e9

Files